CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries
CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Drug Class – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Billion)
2.3. Premium Insights – Based on Primary Interviews
CHAPTER NO. 3: NEUROLOGICAL DISORDER MARKET FORCES & DISEASE TYPE PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Product
CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Component Frontiers – Lucrative Component Categories
4.3 Component Sweet Spots – Emerging Demand Segments
CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Component & Component Revenue
CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1.Import Analysis by Region
6.1.1. Global Neurological Disorder Import Revenue By Region
6.2.Export Analysis by Region
6.2.1. Global Neurological Disorder Export Revenue By Region
CHAPTER NO. 7: COMPETITION ANALYSIS
7.1.Company Market Share Analysis
7.1.1. Global Neurological Disorder: Company Market Share
7.2. Global Neurological Disorder Company Revenue Market Share
7.3.Strategic Developments
7.3.1.Acquisitions & Mergers
7.3.2. New Component Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024
CHAPTER NO. 8: NEUROLOGICAL DISORDER MARKET – BY DRUG CLASS SEGMENT ANALYSIS
8.1. Neurological Disorder Overview by Drug Class Segment
8.1.1. Neurological Disorder Revenue Share By Drug Class
8.2. Cholinesterase Inhibitors
8.3. NMDA Receptor Antagonists
8.4. Antiepileptics
8.5. Antipsychotics
8.6. Antidepressants
8.7. Others
CHAPTER NO. 9: NEUROLOGICAL DISORDER MARKET – BY DISEASE TYPE SEGMENT ANALYSIS
9.1. Neurological Disorder Overview by Disease Type Segment
9.1.1. Neurological Disorder Revenue Share By Disease Type
9.2. Alzheimer’s Disease
9.3. Parkinson’s Disease
9.4. Multiple Sclerosis
9.5. Epilepsy
9.6. Cerebrovascular Diseases
9.7. Others
CHAPTER NO. 10: NEUROLOGICAL DISORDER MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS
10.1. Neurological Disorder Overview by Distribution Channel Segment
10.1.1. Neurological Disorder Revenue Share By Distribution Channel
10.2. Retail Pharmacies
10.3. Hospital Pharmacies
10.4. Online Pharmacies
CHAPTER NO. 11: NEUROLOGICAL DISORDER MARKET – REGIONAL ANALYSIS
11.1.Neurological Disorder Overview by Region Segment
11.1.1. Global Neurological Disorder Revenue Share By Region
11.1.2.Regions
11.1.3.Global Neurological Disorder Revenue By Region
11.1.4. Drug Class
11.1.5.Global Neurological Disorder Revenue By Drug Class
11.1.6.Disease Type
11.1.7. Global Neurological Disorder Revenue By Disease Type
11.1.8. Distribution Channel
11.1.9. Global Neurological Disorder Revenue By Distribution Channel
CHAPTER NO. 12: NORTH AMERICA NEUROLOGICAL DISORDER MARKET – COUNTRY ANALYSIS
12.1. North America Neurological Disorder Overview by Country Segment
12.1.1.North America Neurological Disorder Revenue Share By Region
12.2.North America
12.2.1. North America Neurological Disorder Revenue By Country
12.2.2.Drug Class
12.2.3.North America Neurological Disorder Revenue By Drug Class
12.2.4.Disease Type
12.2.5. North America Neurological Disorder Revenue By Disease Type
12.2.6.Distribution Channel
12.2.7. North America Neurological Disorder Revenue By Distribution Channel
2.3.U.S.
12.4.Canada
12.5.Mexico
CHAPTER NO. 13: EUROPE NEUROLOGICAL DISORDER MARKET – COUNTRY ANALYSIS
13.1. Europe Neurological Disorder Overview by Country Segment
13.1.1. Europe Neurological Disorder Revenue Share By Region
13.2.Europe
13.2.1.Europe Neurological Disorder Revenue By Country
13.2.2.Drug Class
13.2.3.Europe Neurological Disorder Revenue By Drug Class
13.2.4.Disease Type
13.2.5. Europe Neurological Disorder Revenue By Disease Type
13.2.6.Distribution Channel
13.2.7. Europe Neurological Disorder Revenue By Distribution Channel
13.3.UK
13.4.France
13.5.Germany
13.6.Italy
13.7.Spain
13.8.Russia
13.9. Rest of Europe
CHAPTER NO. 14: ASIA PACIFIC NEUROLOGICAL DISORDER MARKET – COUNTRY ANALYSIS
14.1.Asia Pacific Neurological Disorder Overview by Country Segment
14.1.1. Asia Pacific Neurological Disorder Revenue Share By Region
14.2.Asia Pacific
14.2.1. Asia Pacific Neurological Disorder Revenue By Country
14.2.2.Drug Class
14.2.3. Asia Pacific Neurological Disorder Revenue By Drug Class
14.2.4.Disease Type
14.2.5.Asia Pacific Neurological Disorder Revenue By Disease Type
14.2.5.Distribution Channel
14.2.7. Asia Pacific Neurological Disorder Revenue By Distribution Channel
14.3.China
14.4.Japan
14.5.South Korea
14.6.India
14.7.Australia
14.8.Southeast Asia
14.9. Rest of Asia Pacific
CHAPTER NO. 15: LATIN AMERICA NEUROLOGICAL DISORDER MARKET – COUNTRY ANALYSIS
15.1. Latin America Neurological Disorder Overview by Country Segment
15.1.1.Latin America Neurological Disorder Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Neurological Disorder Revenue By Country
15.2.2.Drug Class
15.2.3. Latin America Neurological Disorder Revenue By Drug Class
15.2.4.Disease Type
15.2.5. Latin America Neurological Disorder Revenue By Disease Type
15.2.6.Distribution Channel
15.2.7.Latin America Neurological Disorder Revenue By Distribution Channel
15.3.Brazil
15.4.Argentina
15.5.Rest of Latin America
CHAPTER NO. 16: MIDDLE EAST NEUROLOGICAL DISORDER MARKET – COUNTRY ANALYSIS
16.1. Middle East Neurological Disorder Overview by Country Segment
16.1.1. Middle East Neurological Disorder Revenue Share By Region
16.2.Middle East
16.2.1. Middle East Neurological Disorder Revenue By Country
16.2.2.Drug Class
16.2.3. Middle East Neurological Disorder Revenue By Drug Class
16.2.4.Disease Type
16.2.5. Middle East Neurological Disorder Revenue By Disease Type
16.2.6. Distribution Channel
16.2.7.Middle East Neurological Disorder Revenue By Distribution Channel
16.3.GCC Countries
16.4. Israel
16.5. Turkey
16.6.Rest of Middle East
CHAPTER NO. 17: AFRICA NEUROLOGICAL DISORDER MARKET – COUNTRY ANALYSIS
17.1. Africa Neurological Disorder Overview by Country Segment
17.1.1. Africa Neurological Disorder Revenue Share By Region
17.2. Africa
17.2.1.Africa Neurological Disorder Revenue By Country
17.2.2.Drug Class
17.2.3.Africa Neurological Disorder Revenue By Drug Class
17.2.4.Disease Type
17.2.5. Africa Neurological Disorder Revenue By Disease Type
17.2.6.Distribution Channel
17.2.7. Africa Neurological Disorder Revenue By Distribution Channel
17.3. South Africa
17.4.Egypt
17.5.Rest of Africa
CHAPTER NO. 18: COMPANY PROFILES
18.1. AbbVie Inc.
18.1.1.Company Overview
18.1.2.Component Portfolio
18.1.3.Financial Overview
18.1.4.Recent Developments
18.1.5.Growth Strategy
18.1.6.SWOT Analysis
18.2. Amneal Pharmaceuticals Inc.
18.3. Biogen Idec
18.4. Boehringer Ingelheim International GmbH
18.5. F. Hoffmann-La Roche Ltd
18.6. Johnson & Johnson Services, Inc.
18.7. Alseres Pharmaceuticals, Inc.
18.8. BANYAN BIOMARKERS, INC.
18.9. Bio-Rad Laboratories, Inc.
18.10. DiaGenic ASA
